EMA SAYS PRAC RECOMMENDED CHANGE TO PRODUCT INFORMATION FOR REMDESIVIR TO INCLUDE SINUS BRADYCARDIA AS ADVERSE REACTION OF UNKNOWN FREQUENCY FOR MEDICINE
* EMA SAYS PRAC CONCLUDED THAT A CAUSAL RELATIONSHIP BETWEEN USE OF REMDESIVIR AND ADVERSE EVENT OF BRADYCARDIA IS AT LEAST A REASONABLE POSSIBILITY
* EMA SAYS DHPC IS INTENDED TO INFORM HEALTHCARE PROFESSIONALS ABOUT OUTCOME OF A SIGNAL PROCEDURE AND NEW RECOMMENDATIONS FOR USE OF XELJANZ
* EMA SAYS PRAC ADVISING XELJANZ BE USED IN PATIENTS OVER 65 YRS, CURRENT/PAST SMOKERS, OTHER CARDIOVASCULAR RISK FACTORS IF NO SUITABLE ALTERNATIVE AVAILABLE
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.